Long-term adherence and response to botulinum toxin in different indications.
John-Ih LeeAlexander JansenSara SamadzadehUlrike KahlenMarek MollMarius RingelsteinGiulia SoncinHans BigalkeOrhan AktasAlexia-Sabine MoldovanJulia WaskoenigSebastian JanderMichael GliemAlfons SchnitzlerHans-Peter HartungHarald HefterPhilipp AlbrechtPublished in: Annals of clinical and translational neurology (2020)
The treatment indication determines long-term adherence and self-perceived symptom reduction in BoNT-A therapy, which are better in BSP, HFS, and CD patients than in ODT and SPAS patients. MHDA-ABs had a significant impact on global self-perceived symptom reduction, but with only a limited degree.